STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #2877 by analyst upside · 2026-08-13
ELV
Elevance Health, Inc.
Healthcare · Market Cap $87B · P/E 17.3x
ANALYST PRICE TARGET
+12.5%
implied upside to consensus target
Current Price $399.14
Consensus Target $449.1
Bull Target $492.0
Bear Target $393.0
Analysts Covering 21
ANALYST CONSENSUS - BUY
Strong Buy
3
Buy
11
Hold
7
Sell
0
52-Week Low $274.84
52-Week High $436.24
YTD Return +13.8%
FUNDAMENTALS
Market Cap $87B
P/E Ratio (TTM) 17.3x
Forward P/E 13.5x
EPS (TTM) $23.11
PEG Ratio 1.41
Dividend Yield 1.76%
Revenue (TTM) $201.1B
Profit Margin 2.5%
52-WEEK RANGE
52-Week Low $274.84
52-Week High $436.24
Current Price $399.14
Bear Target $393.0
Bull Target $492.0
● Now $399.14 ● Target $449.1
TRADING DATA
Avg Volume 1.6M
YTD Return +13.8%
Analyst Count 21
Consensus Buy
Upside to Target +12.5%
Last Updated 2026-08-13

ANALYST SUMMARY

Elevance Health, Inc. (ELV) is currently trading at $399.14 with a Wall Street consensus price target of $449.1, implying potential upside of 12.5% over the next 12 months. 21 analysts currently cover ELV, with a consensus rating of Buy - 67% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $492.0, while the most cautious has a target of $393.0.

ELV operates in the Healthcare sector with a market capitalisation of $87B. The stock is up 13.8% year-to-date and is currently trading near the upper end of its 52-week range of $274.84 – $436.24.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for ELV, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Mizuho - Reiterated
Outperform → Outperform 2026-06-08 Building track record
JP Morgan - Reiterated
Overweight → Overweight 2026-06-08 43% win rate (7 calls)
B of A Securities - Reiterated
Buy → Buy 2026-06-04 Building track record
Morgan Stanley - Reiterated
Equal-Weight → Equal-Weight 2026-06-04 Building track record
Truist Securities - Reiterated
Buy → Buy 2026-06-01 Building track record
Barclays - Reiterated
Overweight → Overweight 2026-05-26 Building track record
UBS - Reiterated
Buy → Buy 2026-05-22 33% win rate (6 calls)
Mizuho - Reiterated
Outperform → Outperform 2026-05-20 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
63
out of 100
Coverage depth
24/30
Consensus clarity
25/30
Vote unanimity
12/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →